13,14-DIHYDRO-15-KETO PROSTAGLANDIN E2 Property

Boiling point:

538.1±45.0 °C(Predicted)

Density 

1.086±0.06 g/cm3(Predicted)

storage temp. 

−20°C

pka

4.75±0.10(Predicted)

Safety

Hazard Codes 

F,Xn,Xi

Risk Statements 

11-20/21/22-36/37/38-67-66-36

Safety Statements 

16-26-36

RIDADR 

UN 1231 3/PG 2

WGK Germany 

3

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Warning

Hazard statements

H302Harmful if swallowed

H312Harmful in contact with skin

H315Causes skin irritation

H319Causes serious eye irritation

H332Harmful if inhaled

H335May cause respiratory irritation

H351Suspected of causing cancer

Precautionary statements

P261Avoid breathing dust/fume/gas/mist/vapours/spray.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

13,14-DIHYDRO-15-KETO PROSTAGLANDIN E2 Chemical Properties,Usage,Production

Description

13,14-dihydro-15-keto Prostaglandin E₂ (13,14-dihydro-15-keto PGE₂) is a metabolite of PGE₂ and the primary PGE₂ metabolite in plasma. It is formed from PGE₂ via a 15-keto PGE₂ intermediate by 15-oxo-PG Δ¹³ reductase. Unlike PGE₂, 13,14-dihydro-15-keto PGE₂ does not bind effectively to the PGE₂ receptors EP₂ and EP₄ expressed in CHO cells (K_is = 12 and 57 μM, respectively) or induce adenylate cyclase activity in the same cells (EC₅₀s = >18 and >38 μM, respectively). Levels of 13,14-dihydro-15-keto PGE₂ are increased in the plasma of women in the third trimester of pregnancy and in women during and immediately after labor and delivery. Levels of 13,14-dihydro-15-keto PGE₂ levels are decreased in tumor tissue compared to adjacent non-cancerous tissue isolated from patients with non-small cell lung cancer (NSCLC).

Uses

13,14-Dihydro-15-ketoPGE2 is a primary metabolite of PGE2 in plasma.

Definition

ChEBI: The 13,14-dihydro derivative of 15-oxo-prostaglandin E2.